Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite
events exists following long term treatment with TAK-875 compared with placebo.